{"organizations": [], "uuid": "d1d98c02964294064187d48b2d5457cbe5f0ab83", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/03/globe-newswire-innomar-strategies-enhances-commercialization-expertise-with-acquisition-of-therapeutic-products-inc.html", "country": "US", "domain_rank": 767, "title": "Innomar Strategies Enhances Commercialization Expertise with Acquisition of Therapeutic Products Inc.", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.737, "site_type": "news", "published": "2018-05-03T16:30:00.000+03:00", "replies_count": 0, "uuid": "d1d98c02964294064187d48b2d5457cbe5f0ab83"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/03/globe-newswire-innomar-strategies-enhances-commercialization-expertise-with-acquisition-of-therapeutic-products-inc.html", "ord_in_thread": 0, "title": "Innomar Strategies Enhances Commercialization Expertise with Acquisition of Therapeutic Products Inc.", "locations": [], "entities": {"persons": [{"name": "anne tomalin", "sentiment": "none"}], "locations": [{"name": "canada", "sentiment": "none"}, {"name": "oakville", "sentiment": "none"}, {"name": "ontario", "sentiment": "none"}, {"name": "innomar", "sentiment": "none"}, {"name": "innomar strategies", "sentiment": "none"}, {"name": "north america", "sentiment": "none"}], "organizations": [{"name": "acquisition of therapeutic products inc", "sentiment": "negative"}, {"name": "amerisourcebergen", "sentiment": "none"}, {"name": "therapeutic products inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "OAKVILLE, Ontario, May 03, 2018 (GLOBE NEWSWIRE) -- Innomar Strategies, Canada’s leading specialty pharmaceuticals service provider and a part of AmerisourceBergen, announced today the acquisition of regulatory consulting firm Therapeutic Products Inc. (TPIreg). With the addition of TPIreg, Innomar is the first full service distributor and support services company in the specialty marketplace in Canada to offer a comprehensive portfolio of commercialization services.\nSince 2013, TPIreg has been a leader in the Canadian healthcare landscape, with expertise in providing regulatory and quality assurance consultation to specialty pharmaceutical manufacturers in North America, as well as international companies focused on entry into the Canadian market. Anne Tomalin, Founder of TPIreg, will join Innomar. She is one of Canada’s leading experts in regulatory affairs and brings more than 25 years of industry experience to the company along with significant relationships with Canadian regulators.\n“At Innomar Strategies, we are committed to advancing the commercialization of specialty pharmaceuticals and delivering value to our patients and partners across the Canadian healthcare system,” said Guy Payette, President, Innomar Strategies. “TPIreg is dedicated to this same mission and we believe that together, our best-in-class combination of resources, solutions and expertise allows us to offer customers a true integration of commercialization services, including supporting full market authorization into Canada.”\nAccompanying Tomalin is her team of renowned experts who will support Innomar in the key areas of Regulatory Marketing and clinical trial applications, Quality Assurance, Drug Establishment Licensing (DEL) and support, and post marketing regulatory activities regarding safety and supply chain management.\n“TPIreg will benefit from Innomar’s broad expertise and looks forward to contributing to a suite of commercialization services for companies wanting to enter the pharmaceutical market in Canada,” said Anne Tomalin, President, TPIreg. “We are excited to join Innomar and accelerate our pace of innovation.”\nInnomar Strategies offers a broad suite of customized, end-to-end commercialization solutions, including market access consulting, patient support programs, nursing and clinic services, and specialty pharmacy and logistics management.\nAbout Innomar Strategies\nInnomar Strategies, a part of AmerisourceBergen, is the leading patient support provider in the Canadian specialty biopharmaceutical market. We deliver end-to-end commercialization solutions to improve product access, increase supply chain efficiency and enhance patient care. Strategic consulting, patient support programs, nursing and clinical services, and specialty pharmacy and logistics are just a few of our key areas of specialization. We partner closely with manufacturers, healthcare providers, pharmacies and payers to ensure patients have consistent and reliable access to specialty medication. With our integrated approach and commitment to best-in-class care, Innomar Strategies helps navigate the patient journey to optimize health outcomes. Visit us at www.innomar-strategies.com .\nAbout AmerisourceBergen\nAmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work—and powered by our 21,000 associates—we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #11 on the Fortune 500, with more than $150 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at amerisourcebergen.com .\nContact:\nLauren Esposito\nDirector of External Communications\nAmerisourceBergen\n610.576.3842\nLMoyer@amerisourcebergen.com\nSource: Innomar Strategies", "external_links": ["https://www.globenewswire.com/Tracker?data=9_KsXMXg3fd6DD69axI7ErmNTu_yMjgbyv7G_H_oLCK3Gj4BWXrvMkAwceTkD6eD3qa_DsyDA-fzYS0qPktmv9030zoA_xFj9MskNGdtM7g=", "https://www.globenewswire.com/Tracker?data=j40vu8OUdrgRiL-WvIVodMX_Vt8aRBHGi9xTCBOT7PSUQ5rMxupj_8K5hvPbayZtNDKwf420aSgJ14laiLG-r2yTSDtF0RNGnocEMEMNulun_beBtkAO_Di8BPuSV_eM", "https://www.globenewswire.com/NewsRoom/AttachmentNg/33ff69a8-7571-4b6c-ba62-ae7992f0c595", "https://www.globenewswire.com/Tracker?data=M8TPk3rZxkL2Sapg8g-v97dpH1_D49kWMwidGdTFSvGGW_zV7sFmTMhp4LZjgKd1HZKZeHLHKEljjjA-BKf-sbXaBWq3FQ8fonm6h1WONw7y3WBHsJorQkGFeiVCNEMI"], "published": "2018-05-03T16:30:00.000+03:00", "crawled": "2018-05-03T17:57:20.018+03:00", "highlightTitle": ""}